With repeated exposure of Osemozotan at the 5-HT1A receptors, there seems to be no change in the number of receptors, which is not typically seen with pharmaceutical agonists.
With repeated exposure of Osemozotan at the 5-HT1A receptors, there seems to be no change in the number of receptors, which is not typically seen with pharmaceutical agonists.